Enabling mass adoption of oligonucleotide medicines

Oligonucleotide medicines can turn daily medications into just 1 or 2 yearly doses, transforming outcomes across cardiometabolic, weight loss, and genetic conditions.
‍
But none of that potential reaches patients if production can't scale. GemBio was started to solve this issue.